Literature DB >> 19780257

Biobehavioral factors in chemotherapy-induced nausea and vomiting.

Joseph A Roscoe1, Gary R Morrow, Jane T Hickok, Karen M Mustian, Abhay R Shelke.   

Abstract

Although emesis can be considered a reflex to clear toxins from the body and involves mostly lower brain structures, nausea's purpose appears to be a warning signal to the individual to not engage in behaviors that he or she was doing at the time. As such, it involves the functioning of cognition and memory from higher developed neural structures. Given this, it should not be surprising that biobehavioral factors are important in predicting and controlling nausea. This article reviews the individual characteristics that are clinically useful in predicting which patients will have an increased probability of experiencing nausea or emesis during chemotherapy treatment, and also briefly review psychologic and biobehavioral treatments that can be useful in managing chemotherapy-related nausea.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 19780257     DOI: 10.6004/jnccn.2004.0039

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  8 in total

1.  Chemotherapy-Induced Nausea and Vomiting.

Authors:  Karen M Mustian; Tom V Darling; Michelle C Janelsins; Pascal Jean-Pierre; Joseph A Roscoe; Gary R Morrow
Journal:  US Oncol       Date:  2008

Review 2.  Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.

Authors:  Michelle C Janelsins; Mohamedtaki A Tejani; Charles Kamen; Anita R Peoples; Karen M Mustian; Gary R Morrow
Journal:  Expert Opin Pharmacother       Date:  2013-04       Impact factor: 3.889

3.  Treatment of Nausea and Vomiting During Chemotherapy.

Authors:  Karen M Mustian; Katie Devine; Julie L Ryan; Michelle C Janelsins; Lisa K Sprod; Luke J Peppone; Grace D Candelario; Supriya G Mohile; Gary R Morrow
Journal:  US Oncol Hematol       Date:  2011

4.  Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).

Authors:  Lisa Kottschade; Paul Novotny; Alan Lyss; Miroslaw Mazurczak; Charles Loprinzi; Debra Barton
Journal:  Support Care Cancer       Date:  2016-01-15       Impact factor: 3.603

5.  Prevalence and determinants of fatigue in patients with moderate to severe chronic GvHD.

Authors:  A Im; S A Mitchell; S M Steinberg; L Curtis; A Berger; K Baird; Z Kuzmina; G Joe; L E Comis; M Juckett; D Avila; J Baruffaldi; L Masuch; F Pirsl; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2016-02-01       Impact factor: 5.483

6.  Netupitant PET imaging and ADME studies in humans.

Authors:  Tulla Spinelli; Selma Calcagnile; Claudio Giuliano; Giorgia Rossi; Corinna Lanzarotti; Stuart Mair; Lloyd Stevens; Ian Nisbet
Journal:  J Clin Pharmacol       Date:  2013-11-08       Impact factor: 3.126

7.  Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial.

Authors:  Tulla Spinelli; Cecilia Moresino; Sybille Baumann; Wolfgang Timmer; Armin Schultz
Journal:  Springerplus       Date:  2014-07-29

8.  Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy.

Authors:  Zhihuang Hu; Wenhua Liang; Yunpeng Yang; Dorothy Keefe; Yuxiang Ma; Yuanyuan Zhao; Cong Xue; Yan Huang; Hongyun Zhao; Likun Chen; Alexandre Chan; Li Zhang
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.